FDA accepted Milestone's response to the Complete Response Letter (CRL).
3 reports, 3 independent
Updated Thu 00:00
No new developments lately
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted Milestone's response to the Complete Response Letter (CRL).
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Milestone drug receives FDA approval after previous CRL response acceptance.1 source
CRL from FDA prompts sales forecast delay for company associated with Andy Hsieh.1 source
FDA accepted Milestone's response to the CRL on July 11, 2025.1 source
Keep exploring
The entities involved
Related events
- An unnamed company secured regulatory approval in July 2025, leading to a $2.5 million milestone reported today.
- The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.
- FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.
- FDA approval enables commercial opportunity involving CBRE Group.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- manilatimes.net
- benzinga.com
- GlobeNewswireMilestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase